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Abstract
Objective Phenylketonuria (PKU) is an inherited metabolic
disease characterized by plasma hyperphenylalaninemia and
several neurological symptoms that can be controlled by
rigorous dietetic treatment. The cellular mechanisms underly-
ing impaired brain functions are still unclear. It has been
proposed, however, that phenylalanine interference in cogni-
tive functions depends on impaired dopamine (DA) transmis-
sion in the prefrontal cortical area due to reduced availability
of the precursor tyrosine. Here, using Pahenu2 (ENU2) mice,
the genetic murine model of PKU, we investigated all meta-
bolic steps of catecholamine neurotransmission within the
medial preFrontal Cortex (mpFC), availability of the precur-
sor tyrosine, synthesis and release, to find an easy way to
reinstate normal cortical DA neurotransmission.
Methods and results Analysis of blood and brain levels of
tyrosine showed reduced plasma and cerebral levels of
tyrosine in ENU2 mice. Western blot analysis demonstrated
deficient tyrosine hydroxylase (TH) protein levels in mpFC
of ENU2 mice. Cortical TH activity, determined in vivo by
measuring the accumulation of l-3,4-dihydroxyphenylala-
nine (L-DOPA) in mpFC after inhibition of L-aromatic acid
decarboxylase with NSD-1015, was reduced in ENU2 mice.
Finally, a very low dose of L-DOPA, which bypasses the
phenylalanine-inhibited metabolic steps, restored DA pre-
frontal transmission to levels found in healthy mice.
Conclusion The data suggests that a strategy of using tyro-
sine supplementation to treat PKU is unlikely to be effec-
tive, whereas small dose L-DOPA administration is likely to
have a positive therapeutic effect.
Introduction
Phenylketonuria (PKU; McKusick 2610600) is an inherited
metabolic disease caused by a deficiency of the enzyme
phenylalanine hydroxylase, which is necessary to convert
phenylalanine to tyrosine. This results in accumulation of
phenylalanine (> 20 mg/dl), known as hyperphenylalanine-
mia, and reduction of tyrosine concentrations in the blood
and brain. Treatment of PKU requires maintaining blood
phenylalanine within an acceptable range (between 2 and 10
mg/dl) by restricting phenylalanine from the diet. If the
disease is untreated, patients develop severe mental retarda-
tion and neuropathological signs. Compliance with a rigid
low phenylalanine diet is difficult (Giovannini et al 2007;
MacDonald 2000), and it is still unknown when or if the diet
can be safely interrupted (De Roche and Welsh 2008;
Stemerdink et al 2000; Diamond et al 1994). Indeed, evi-
dence indicates that even mildly elevated blood phenylala-
nine levels induce deficits in cognitive functions involving
the prefrontal cortical area (Brumm et al 2004: Channon et
al 2004; De Roche and Welsh 2008; Diamond et al 1994;
Huijbregts et al 2002; Leuzzi et al 2004; Schmidt et al 1994;
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Smith et al 2000; White et al 2002; Stemerdink et al 2000),
in particular executive abilities. This suggests that excess
phenylalanine interferes with cortical functioning. The me-
dial prefrontal cortex (mpFC) is widely innervated by bio-
genic aminergic neurons, which have a major role in
emotion and cognitive functions (Arnsten and Robbins
2002; Lapiz and Morilak 2006; Aston-Jones and Cohen
2005; Goldman-Rakic 1999; Clarke et al 2004, 2005,
2006; Walker et al 2009). Moreover, there are reports of
reduced levels of biogenic amines in post mortem brain
tissue (McKean 1972), low levels of biogenic amine metab-
olites in cerebrospinal fluid of patients with hyperphenyla-
laninemia (Bonafé et al 2001; Butler et al 1981) and reduced
brain amine levels and metabolism in PAHenu2 mice (ENU2)
(Puglisi-Allegra et al 2000; Pascucci et al 2002, 2008), that
is, the genetic murine model of PKU. Dopamine (DA) is the
most studied among cerebral biogenic amines (Diamond
2007; Joseph and Dyer 2003). Although reduction of cere-
bral DA metabolism has been reported in PKU patients
(Diamond et al 1994; Hanley et al 2000; Krause et al
1985; Guttler and Lou 1986; Lou et al 1987; Luciana et al
2004; Lykkelund et al 1988; McKean and Peterson 1970;
Paans et al 1996) and ENU2 mice (Joseph and Dyer 2003;
Pascucci et al 2009; Puglisi-Allegra et al 2000; Smith and
Kang 2000), DA metabolism in mpFC of PKU organisms
has not been investigated until now. Therefore, it is difficult
to determine the mechanisms by which high blood phenyl-
alanine levels reduce cortical DA biosynthesis (De Groot et
al 2010; Martynyuk et al 2010).
ENU2 mice represent a qualified model for clarifying
neurochemical deficits in pFC of PKU organisms, because
they are characterized by a biochemical phenotype that
closely resembles untreated human PKU, as well as by
reduced enzymatic activity of phenylalanine hydroxylase,
high blood phenylalanine levels, hypomyelination, bio-
chemical and behavioural deficits (Andolina et al 2010;
Cabib et al 2003; Embury et al 2007; Glushakov et al
2005; Joseph and Dyer 2003; Martynyuk et al 2005;
Pascucci et al 2002, 2008, 2009; Puglisi-Allegra et al
2000; Smith and Kang 2000; Zagreda et al 1999). In partic-
ular, previous data showed deficits in DA and norepineph-
rine (NE) metabolism in the mpFC of ENU2 mice (Joseph
and Dyer 2003; Puglisi-Allegra et al 2000; Pascucci et al
2009). Since DA availability in mpFC is very important in
executive functions, the elucidation of the mechanism by
which phenylalanine reduces cortical DA metabolism is
essential. Thus, the present study was aimed at investigating
catecholaminergic metabolism in the mpFC of ENU2 mice
and at suggesting strategy to reinstate normal cortical cate-
cholamine levels.
First, we investigated tyrosine blood and brain levels in
order to evaluate the influence of excess phenylalanine on
brain availability of catecholamine precursor. Second, we
evaluated expression and in vivo activity of the tyrosine
hydroxylase (TH) enzyme in mpFC of ENU2 mice. Finally,
we evaluated the effect of l-3,4-dihydroxyphenylalanine
(L-DOPA), the direct DA precursor, on activation of the
frontal cortical catecholaminergic transmission in the presence
of high circulating phenylalanine levels. Since restraint stress
is known to induce a clear-cut increase of amine outflow in the
mpFC of rodents (Cuadra et al 2001; Matuszewich et al 2002;
Pascucci et al 2007), and phenylketonuric mice are unable to
activate catecholamine release under stress (Pascucci et al
2009), we assessed the effect of L-DOPA on cortical catechol-
amine release of restrained ENU2 mice.
Materials and methods
Animals
Homozygous (-/-) PahEnu2 (ENU2) and (+/+) PahEnu2 (WT)
male mice of the background strain (BTBR) were obtained
from heterozygous mating. Genetic characterization was
performed on DNA prepared from tail tissue using the
Easy DNA Kit (Invitrogen, Carlsbad, CA, USA). The
enu2 mutation was detected after PCR amplification of exon
7 of the Pah gene and digestion with Alw261 restriction
enzyme (Promega corporation, Madison, Wi, USA) as de-
scribed (Pascucci et al 2008). At postnatal day 28, animals
(sex matched) were housed 2-4 per standard breeding cage
with food and water ad libitum on a 12:12h dark: light cycle
(light on 07.00 am -07.00 pm h). Experiments started when
animals reached 8 weeks of age. All mice were housed
individually 24 h before surgery for microdialysis. Naive
animals were used for each experiment.
All experiments were conducted in accordance with
European legislation (EEC no. 86/609), Italian national leg-
islation (DL no. 116/92) governing the use of animals for
research, and the guidelines of the National Institutes of
Health on the use and care of laboratory animals.
Drugs
Chloral hydrate, NSD-1015, and L-DOPA were purchased
from Sigma-Aldrich (St. Luis, MO, USA). NSD-1015 was
dissolved in artificial CSF and perfused through the micro-
dialysis probe. Chloral hydrate (450 mg/kg) and L-DOPA
(0.5, 1, 2.5 mg/kg) were dissolved in saline (0.9 % NaCl)
and injected i.p. in a volume of 10 ml/kg.
Brain and blood assay
For brain and blood phenylalanine and tyrosine assay, WT
(n06) and ENU2 (n06) mice were sacrificed by decapitation.
Brains and blood were prepared for biochemical analysis.
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First, the brains were removed, frozen and stored in
liquid nitrogen until the day of biochemical assay. Frozen
whole brains were weighed and homogenized in 0.05M
HClO4 (1:100 ml/mg). The homogenates were centrifuged
at 10000 x g for 20 min at 4 °C.
Blood samples for phenylalanine and tyrosine quantifi-
cation were placed in heparinized tubes and centrifuged at
2,500 rpm, at +4 °C, for 10 min. An aliquot of supernatant
was collected, and transferred to a new tube with 35 % 5-
sulfosalicylic acid (10:1 vol/vol), and centrifuged at 8000
rpm, at +4 °C, for 5 min.
Blood and brain samples were allowed to react with the
same volume of o-phthaldialdehyde reagent (67.1 mg of
o-phthaldialdehyde dissolved in 1.0 ml of methanol plus
50 µl of mercaptoethanol and diluted in 9 ml of borate buffer,
0.4 mM, pH 9.5). After a 2-min reaction time, the sample was
transferred to the HPLC system coupled with a fluorescence
detector (Waters 474 Model). The excitation and emission
wavelengths were set at 330 and 480 nm, respectively.
Nova-Pack C18 (3.9 x 150 mm) and Sentry Guard Nova-
Pack C18 (3.9 x 20 mm; Waters Assoc.) columns were used.
The flow rate was 1.2 ml/min. The mobile phase consisted of
35 % methanol in 0.1 M Na-phosphate buffer, pH 6.5.
Western bolt analysis
Brains of mice from the different groups (WT, n08; ENU2,
n08) were removed, frozen and then fixed vertically on the
freeze plate of a freezing microtome maintained at -10 °C.
Punches of mpFC (Fig. 1a) were obtained from frozen brain
slices as previously reported (Puglisi-Allegra et al 2000) and
stored in liquid nitrogen until the day of assay. Each mpFC
tissue sample was homogenized at 4 °C in lysis buffer [20
mM Tris (pH 7.4), 1 mM EDTA, 1 mM EGTA, 0,1 % Triton
X-100] with protease inhibitor cocktail (Sigma-Aldrich, St.
Louis, MO, USA). Tissue extract was centrifuged at 12000
g at 4 °C for 15 min. The supernatant fluid was removed and
stored at – 80. Samples were heated at 95 °C for 3 min and
protein (15 mg) was separated by SDS-PAGE (10 % gel).
Membranes were rinsed in Tris- buffered saline (TBS),
then blocked in 5 % non-fat milk in TBS with 0.1 % Tween
(TBS-T) for 1.5 h at room temperature in TBS-T and incu-
bated overnight in anti-TH antibody (Chemicon, Temecula,
CA, USA) (1:3000 dilution) diluted in 3 % BSA, followed
by goat anti-rabbit IgG (H+L) AP conjugate (1:2000 dilu-
tion; Santa Cruz Biotechnology, Santa Cruz, CA, USA) in
2 % non-fat milk in TBS-T, and developed with the ECL-R
reaction (Amersham). The film signals were digitally
scanned and quantified using densitometric image software
(imagej 64), normalized for β-actin level.
In vivo microdialysis
All mice were anesthetized with chloral hydrate, mounted in
a stereotaxic frame (David Kopf Instruments, Tujunga, CA)
and implanted unilaterally with a guide cannula (stainless
steel, shaft outer diameter of 0.38 mm, length 1 mm;
Metalant AB, Stockholm, Sweden), fixed with epoxy glue
and dental cement, into the mpFC (Fig. 1a; AP, +2.8; L, 0.6;
according to the Franklin and Paxinos atlas, 2001).
Fig. 1 Reduced expression and in vivo activity of TH in mpFC of
ENU2 mice. (a) Schematic representation of mpFC. (b) Western blot of
TH protein obtained from mpFC of ENU2 and WT mice and (c)
quantification of protein using chemiluminescence (mean ± S.E.M.)
indicated reduced enzyme availability in mutant mice. Detection of β-
actin was used as loading control. (d) Enzymatic activity of TH was
determined measuring accumulation of transient intermediate L-DOPA
in vivo during continuous infusion of 20 µM NSD-1015. Dialysates
were collected at 20-min intervals. Results are expressed as percent
changes (means ± S.E.M.) from basal values. Statistical analyses were
performed on raw data. Comparison of time course of changes in
extracellular levels of L-DOPA in pFC of ENU2 and WT mice reveals
reduction of L-DOPA accumulation in ENU2 mice, significant from
160 min onwards. * P<0.05 versus basal values. § P<0.05 in compar-
ison with WT
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Placement of probes in mpFC was evaluated by methylene
blue staining. Only data from mice with correctly placed
cannula are reported.
Mice were allowed to recover in their home cage. The probe
(2 mm long;MAB 4 cuprophane microdialysis probe,Metelant
AB) was introduced 24 h before microdialysis experiments.
The mice were lightly anesthetized with chloral hydrate to
facilitate manual insertion of the probe into the guide cannula.
The dialysis probe was connected to a CMA/100 pump
(Carnegie Medicine, Stockholm, Sweden) through PE 20 tub-
ing (Metalant AB) and an ultralow torque dual-channel liquid
swivel (model 375/D/22QM; Instech Laboratories, Plymouth
Meeting, PA) to allow free movement. Artificial cerebrospinal
fluid (147 mMNaCl, 1 mMMgCl, 1.2 mMCaCl2, 4 mMKCl)
was pumped through the dialysis probe at a constant flow rate
of 2 μl/min. The day of the experiments, each animal was
transferred to a Plexiglas cylinder provided with microdialysis
equipment (Instech Laboratories, Inc.) and with home cage
bedding on the floor. Dialysis perfusion was started 1 h later
and mice were left undisturbed for 2 h before baseline samples
were collected. Dialysate was collected every 20 min. The
mean concentration of the three samples collected immediately
before treatment (<10 % variation) was taken as basal concen-
tration. Twenty microliters of each dialysate sample were trans-
ferred to HPLC systems for analysis.
In vivo TH activity Cortical TH activity in WT (n08) and
ENU2 (n08) mice was determined in vivo by the accumula-
tion of L-DOPA in mpFC after inhibition of L-aromatic acid
decarboxylase with NSD-1015 (Sigma-Aldrich, St. Louis,
MO, USA). Ringer solution containing 20 μM of NSD-1015
was pumped through the dialysis probe at a constant flow rate
of 2 μl/min, and dialysates were collected at 20-min intervals
for 260 min. L-DOPA was assessed by HPLC coupled to an
amperometric detector (Decade II model, Antec Leyden, The
Netherlands). The detector potential was set at +700 mV
against an Ag/AgCl reference electrode. The mobile phase
was previously described (Nakahara et al 2000).
L-DOPA treatment Finally, we evaluated the effect of L-
DOPA administration on prefrontal cortical DA response
to stress in hyperphenylalaninemic mice. DA, DOPAC
(3,4-dihydroxyphenylacetic acid), HVA (homovanilic acid)
and NE levels were determined simultaneously, utilizing the
HPLC system coupled to a coulometric detector (model
5200 °Coulochem II; ESA, Chelmsford, MA). The condi-
tioning cell was set at +400 mV, electrode 1 at +200 mV, and
electrode 2 at -250 mV; the mobile phase was previously
described (Pascucci et al 2007). A Nova-Pack C18 column
(3.9 x 150 mm; Waters) and a Sentry Guard Nova-Pack C18
pre-column (3.9 x 20 mm) maintained at 30 °C were used.
The flow rate was 1.1 ml/min. The detection limit of the
catecholamines assay was 0.1 pg.
First, we identified a per se ineffective dose of systemati-
cally administered L-DOPA by performing a dose-response
study. Naive WT (n06) and ENU2 (n06) mice were injected
i.p. on consecutive days with saline or L-DOPA (0.5, 1, 2.5
mg/kg) and DA and NE in vivo extracellular levels were
assessed. Doses were injected in a random order and sufficient
time was allowed for neurotransmitter to return to basal levels
(no more than 180 min were necessary). No more than two L-
DOPA doses were administered daily.
Last, the effect of systemic administration of a per se
ineffective dose of L-DOPA on only frontal cortical DA and
metabolite response to stress was evaluated, as L-DOPA
inability to increase NE frontal cortical extracellular levels.
Following collection of baseline samples, animals subjected
to the stress experience (WT-sal, n08; ENU2-sal, n08;
ENU2-L-DOPA 0.5, n08) were put in a restraint apparatus
for 2 h and dialyzate samples were collected every 20 min.
The apparatus consisted of an adjustable neck-blocking
support mounted on a Plexiglas base and movable U-
shaped metal piece that could be fixed to the base at the
level of the animal’s hips thus preventing it from turning on
its back (Cabib and Puglisi-Allegra 1991).
Data analysis
The effect of genotype (WT and ENU2) on phenylalanine
and tyrosine brain and blood levels and on brain/blood ratios
was evaluated by one-way ANOVAs.
Regarding western blot data, the effect of genotype (WT
and ENU2) on TH protein levels in mpFC was evaluated by
one-way ANOVA.
For microdialysis data, statistical analyses were always
carried out on raw data (concentrations: pg/20 µl). Data
were presented in figures as percent changes from baseline
levels.
The effect of genotype on L-DOPA accumulation in
mpFC was analyzed by repeated-measures ANOVA with
one between factor (genotype, two levels, WT and ENU2)
and one within factor (time, forteen levels, 0, 20, 40, 60, 80,
100, 120, 140, 160, 180, 200, 220, 240, 260 minutes).
The effect of L-DOPA treatment on DA and NE extracel-
lular levels in mpFC of ENU2 and WT mice was analyzed by
repeated-measures ANOVAs with one between factor (treat-
ment, four levels, saline, L-DOPA 0.5, 1, 2.5 mg/kg) and one
within factor (time, seven levels, 0, 20, 40, 60, 80, 100 and
120 minutes).
The effect of L-DOPA treatment on DA, DOPAC and
HVA extracellular levels in mpFC of ENU2 mice sub-
jected to restraint was analyzed by repeated-measures
ANOVAs with one between factor (group, three levels,
WT-sal, ENU2-sal and ENU2-L-DOPA 0.5) and one with-
in factor (time, seven levels, 0, 20, 40, 60, 80, 100 and
120 minutes).
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Results
Blood and brain levels and brain/blood ratio
of phenylalanine and tyrosine in ENU2 and WT mice
To determine whether high phenylalanine levels inhibit ty-
rosine transport across the blood-brain barrier, we measured
phenylalanine and tyrosine blood and brain levels in ENU2
and WT mice (Table 1). The concentration of phenylalanine
was significantly higher in ENU2 than in WT mice, both in
blood (~2500 %) and in brains (~1700 %). For tyrosine
levels, ENU2 showed reduction of blood and brain levels
(~40 %) compared with WT mice. Moreover, phenylalanine
blood/brain ratio was significantly reduced, and tyrosine
blood/brain ratio was not significantly different, in ENU2
compared with WT mice.
Expression and in vivo activity of TH in mpFC of ENU2
and WT mice
Western blot analysis of TH protein (Fig. 1b, c) showed
significant difference between the two genotypes (F1,100
11.25, p<.01), revealing a 40 % reduction of TH protein
levels in mpFC of ENU2 (1.84±.21) in comparison with
WT (1.10±.06) mice.
Figure 1d reports in vivo TH activity in mpFC of ENU2
and WT mice. Statistical analysis revealed significant geno-
type x time interaction (F1,18203.82, p<.05). In WT mice,
blockade of aromatic L-amino acid decarboxylase promoted a
time-dependent increase of frontal cortical L-DOPA outflow
that became significantly higher than basal levels after
120 min, reached maximal levels (233.7 %) at 260 min.
ENU2mice achieved a steady state after 160 min of perfusion,
reaching a maximal increase of 80.2 % at 260 min.
In vivo microdialysis
The two genotypes did not differ for DA cortical basal
outflow (WT00.95±.14 pg/20 l; ENU200.98±0.15 pg/20
µl), while NE extracellular levels from mpFC of ENU2 mice
were significantly reduced (WT02.12±.23 pg/20 µl; ENU20
1.24±0.19 pg/20 µl; F1,1008.64, p<.05), as previously
reported (Pascucci et al 2009), suggesting that compensatory
mechanisms appear to support DA release at the expense of
NE in basal conditions.
Dose-response curve of L-DOPA The dose-dependent effect
of L-DOPA treatment on catecholaminergic frontal cortical
extracellular release was evaluated (Fig. 2a, b). L-DOPA at a
dose of 0.5 mg/kg i.p. had no significant effect on DA
outflow in either group of mice, but at the dose of 1 and
2.5 mg/kg i.p. produced significant increase of DA cortical
extracellular levels (Fig. 2a).
None of these doses of L-DOPA had an effect on extra-
cellular levels of NE in either group, with the exception of a
slight increase at 2.5 mg/kg i.p. in ENU2 mice (Fig. 2b).
Effect of L-DOPA treatment on DA cortical neurotransmis-
sion in stressed ENU2 mice Because L-DOPA treatment
was unable to increase NE frontal cortical extracellular
levels, effect of per se ineffective dose of L-DOPA was
evaluated on frontal cortical DA outflow and turnover (as
measured by their major metabolites, DOPAC and HVA) in
ENU2 and WT stressed mice (Fig. 3). We compared frontal
cortical DA outflow in WT and ENU2 stressed mice follow-
ing saline or L-DOPA (0.5 mg/kg i.p.) treatment. Statistical
analyses revealed a significant group x time interaction
(F18,16803.15, p<.0001). Analyses of DOPAC and HVA
extracellular levels in WT, ENU2-sal and ENU2-L-DOPA
0.5 groups revealed significant group x time interactions
(DOPAC: F12,12603.77, p<.0001; HVA: F12,12603.90,
p<.0001).
As previously reported (Pascucci et al 2009), ENU2
mice did not show the typical increase of prefrontal
cortical DA outflow. Indeed, DA decreased below basal
levels (Fig. 3). Moreover, stress resulted in augmented
DOPAC and HVA extracellular levels in WT but not in
ENU2 mice (Fig. 3), although DOPAC (WT-sal053.34+
8.87 pg/20 μl; ENU2-sal059.20+12.61 pg/20 μl; ENU2-
L-DOPA 0.5059.88±17.09 pg/20 µl) and HVA (WT-sal0
118,12±21.72 pg/20 µl; ENU2-sal0154.83±19.24 pg/20
µl; ENU2-L-DOPA 0.50159.65±27.91 pg/20 µl) basal
levels did not differ between groups. Nevertheless, in
ENU2 mice (similar to WT-sal) treatment with L-DOPA
Table 1 Blood and brain levels and brain/blood ratios of phenylalanine and tyrosine in WT and ENU2 mice
WT ENU2
blood brain brain/blood ratio blood brain brain/blood ratio
Phenylalanine 92.0 + 4.8 2.2 + 0.2 0.023 2334.1 + 143.7b 38.0 + 4.7b 0.016 a
Tyrosine 82.8 + 6.1 3.5 + 0.4 0.043 34.2 + 1.7b 1.27 + 0.2b 0.039
Amino acids levels (μM) in blood and brain samples and blood/brain ratios in WT and ENU2 mice. Values are expressed as means + SEM. a p <
0.05; b p < 0.001 vs WT
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caused an immediate significant increase in DA outflow
(20-60 min) followed by a return to basal levels as well
as partial but significant increase of DOPAC and HVA
extracellular levels.
Discussion
This study demonstrates that the reduced DA concentrations
reported in prefrontal cortical area of PKU mice are mainly
due to reduced cortical expression and activity of the TH
enzyme, supporting the use of L-DOPA to treat cortical
dopaminergic deficits in phenylketonuric subjects.
It is well known that brain amine levels are reduced in
PKU patients and mouse models, and DA is the most
extensively studied neurotransmitter. In particular, reduced
DA availability in mpFC has been proposed as the biochem-
ical mechanism responsible for reduced cognitive perform-
ances observed in PKU patients. It has also been proposed
that DA cortical deficits stem from decreased levels of
Fig. 2 Dose-dependent effect
of L-DOPA on frontal cortical
catecholamine extracellular
levels. Dose-dependent effect
of L-DOPA (0.5, 1.0, 2.5 mg/kg
i.p.) on DA (a) and NE (b)
outflow in the mpFC of WT and
ENU2 mice. Results are
expressed as percent changes
(means ± S.E.M.) from basal
value during 120-min post-
injection. Statistical analyses
were performed on raw data.
Drug was administered to time
0. * P<0.05 vs saline group. §
P<0.05 in comparison with
vehicle-injected mice
Fig. 3 Effect of L-DOPA on dopaminergic cortical neurotransmission
in stressed ENU2 mice. Recovery of DA and metabolite response to
stress in mpFC of ENU2 mice submitted to 120 min of restraint
following systemic administration of 0.5 mg/kg i.p. of L-DOPA. Dial-
ysates were collected at 20-min intervals. Results are expressed as
percent changes (means ± SE) from basal values. Statistical analyses
were performed on raw data. Drug was administered to time 0. * P<
0.05 versus basal values. § P<0.05 compared with vehicle-injected
WT mice
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amino acid tyrosine (“tyrosine/dopamine” theory), the pre-
cursor of DA, and that low levels of tyrosine are a conse-
quence of high phenylalanine levels outcompeting other
amino acids for transport across the blood-brain barrier
(Diamond et al 1994). Although the “tyrosine/dopamine”
theory is strong and empirically supported, controversial
data have been reported. Indeed, dietary supplements of
tyrosine do not improve cognitive performance in PKU
patients (Smith et al 1998), and frontal cortical levels of
tyrosine do not return to normal levels when PKU mice
are placed on the low phenylalanine diet (Joseph and
Dyer 2003). These data indicate that reduced tyrosine
availability alone cannot explain the DA cortical deficits,
suggesting co-existing of several factors. In this study,
we investigated full cortical dopaminergic metabolism in
ENU2 mice in order to elucidate phenylalanine-induced inter-
ferences at each metabolic step and suggest an easy pharma-
cological way to raise cortical dopaminergic levels.
Synthesis of catecholamines occurs via hydroxylation of
tyrosine to L-DOPA by TH. L-DOPA is rapidly decarboxy-
lated by L-aromatic amino acid decarboxylase to DA, which
is then metabolized to NE. Thus, we firstly examined blood
and brain availability of DA precursors. Although the pres-
ence of high phenylalanine and reduced tyrosine blood and
brain levels is well known, the evaluation of brain/blood
ratios for tyrosine and phenylalanine in this study is not
consistent with the hypothesis of phenylalanine-induced
inhibition of amino acid transport to the brain, according
to previously reported data (Joseph and Dyer 2003). In fact,
we observed a significant reduction of blood and brain
tyrosine levels, according to the literature, but found no
significant difference in the brain/blood ratio between phe-
nylketonuric and normal mice, suggesting that reduced brain
levels of tyrosine reflect low tyrosine blood levels more than
reduction of access to the brain. Conversely, when we
compared the phenylalanine brain/blood ratio in both
groups, we found a trend towards reduced phenylalanine
access in the brains of PKU mice, which, however, was
unable to prevent high brain phenylalanine levels.
Second, based on demonstrations that tyrosine is not the
limiting factor on DA biosynthesis (Joseph and Dyer 2003;
Pascucci et al 2009), we investigated cortical availability
and activity of TH. Analysis of Western blot data confirmed
reduced TH protein levels in mpFC of PKU mice (Joseph
and Dyer 2003). Although the decreased protein amount of
TH could be an adaptive downregulation in response to
reduced dopaminergic synthesis, a faster degradation of
the TH protein could not be excluded. Moreover, in vivo
assay of TH cortical activity (measured as accumulation rate
of L-DOPA after blockade of the decarboxylating enzyme)
showed significant reduction in the rate of DA synthesis in
ENU2 vs WT mice. The reduction of L-DOPA accumula-
tion (66 %) was greater than the 40 % reduction seen in TH
protein concentration suggesting other mechanisms causing
TH inhibition. This most likely involves a direct inhibitory
effect of phenylalanine on mpFC TH activity.
So far our data suggestes three complementary factors are
able to explain DA reduced biosynthesis in PKU: decrease
of precursor availability to the brain and reduction of protein
synthesis and activity of TH enzyme. Recently, we demon-
strated that deficits of cortical serotonin biosynthesis in
PKU mice are due to phenylalanine -induced inhibition of
cortical tryptophan hydroxylase activity (Pascucci et al
2009). These results are in agreement with the hypothesis
that phenylalanine influences cortical aminergic transmission
by inhibiting activity of enzymes hydroxylating amino acid
precursors (Curtius et al 1981; McKean 1972; Ogawa and
Ichinose 2006).
Third, based on the reduction of prefrontal cortical TH
protein and activity levels in ENU2 mice, we were able to
identify L-DOPA, the product of tyrosine hydroxylation, as
responsible for increasing DA cortical levels. As previously
reported (Pascucci et al 2009), when ENU2 mice were
subjected to restraint stress, an environmental challenge
known to enhance aminergic release in the mpFC (Page
and Lucki 2002; Pascucci et al 2007), they showed deficits
in the activation of frontal cortical serotoninergic and dopa-
minergic transmission and altered noradrenergic responses.
In particular, no initial increase of DA release followed by
decrease below baseline levels was observed compared with
WT, although basal frontal cortical outflow of DA was
unaffected. Moreover, DA turnover was also affected by
hyperphenylalaninaemia, as shown by reduced DOPAC
and HVA extracellular levels in ENU2-stressed mice, al-
though DA basal levels were unaffected.These results sug-
gest compensatory mechanisms are involved that maintain
suitable DA metabolism necessary to hold basic physio-
logical functions. However, these mechanisms are unable
to sustain the activation solicited by stressful experience.
In order to restore cortical dopaminergic response to
stress, we administered L-DOPA, the proximal precursor
of DA. The L-DOPA dose-response curves obtained in the
ENU2 and WT mice were similar suggesting that the corti-
cal DA metabolic pathway following tyrosine hydroxylation
step is intact. Nevertheless, an alternative possibility cannot
be excluded: i.e. the L-DOPA-induced DA release depends
on serotonergic neurons (Carta et al 2007; Navailles et al
2010; Tanaka et al 1999), wherein L-aromatic amino acid
decarboxylase is also present. The same L-DOPA doses
were unable to increase frontal cortical release of NE, sug-
gesting an impairment of the conversion of DA to NE in
cortical neurons. The administration of a per se ineffective
dose of L-DOPA (0.5 mg/kg i.p.) affected response to stress
in mpFC of ENU2 mice, producing activation of DA and
metabolite response. These results show that DA metabo-
lism in the mpFC is very sensitive to L-DOPA treatment,
J Inherit Metab Dis
suggesting, under stress challenge, an increase of L-DOPA
decarboxylation by DOPA decarboxylase to DA. Although
neurological complications related to prolonged treatment
with L-DOPA have been reported in Parkinson’s disease
patients, the dose used here was well below that associated
with abnormal movements in human and in animal models.
Altogether, our data suggests that DA cortical deficits in
PKU are due to several factors: reduced precursor cerebral
availability, reduced cortical TH protein levels and inhibition
of TH cortical activity. Thus, our data raises doubts about
using tyrosine in PKU patients. A better approach may be
the use of low dose L-DOPAwhich in the PKU mouse is able
to increase cortical DA neurotransmission even in the pres-
ence of high blood and brain phenylalanine levels.
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